IDH mutations, which are a major target of interest in acute myeloid leukemia (AML), are also present in a minority of patients with myelodysplastic syndrome (MDS). Due to the durability of response and favorable tolerability of IDH1 inhibitors,…
After Strong Outcomes in AML, Olutasidenib Shows Response in IDH1+ MDS | Targeted Oncology
